A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials
NCT07040891 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2026-04-23
Summary
The goal of this study is to conduct a pilot stepped-wedge cluster randomized controlled trial (RCT) of the "Just ASK™" training and implementation to increase provider discussions of cancer clinical trials (CCTs) with patients with breast cancer. The main research questions the study aims to answer are:
* Is a cluster RCT feasibility and acceptable? (This will inform the design of a future definitive cluster RCT)
* What are the determinants of the Just Ask training completion and implementation in practice to develop a better understanding for whom the intervention works, and under what circumstances?
* What are the CCT discussion rates pre- and post-intervention?
* What are discussion elements associated with breast cancer trial participation?
The study will be a stepped-wedge cluster RCT in which four participating practices (5-10 clinic members per each cluster) will receive the Just ASK training at different, randomly assigned time points. Clinic team participants will complete the training and develop an implementation strategy of Just ASK at the cluster level. Within each cluster, we will audio-record 10 patient-provider encounters pre-training and 10 encounters post-training to assess discussions of cancer clinical trials with breast cancer patients.
Conditions
Interventions
- BEHAVIORAL
-
Just ASK training
"Just ASK™" is a web-based training designed to help providers understand the impact of assumptions about their patients' interest in cancer clinical trials. The training program aims to increase clinical trial discussions with all eligible cancer patients.
Sponsors & Collaborators
-
Abramson Cancer Center at Penn Medicine
lead OTHER
Principal Investigators
-
Carmen E Guerra, MD · University of Pennsylvania
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-01
- Primary Completion
- 2026-10-31
- Completion
- 2026-10-31
Countries
- United States
Study Locations
More Related Trials
-
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
NCT00014222 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
NCT00887536 ·Status: COMPLETED ·Phase: PHASE3
-
Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00072319 ·Status: COMPLETED ·Phase: PHASE2
-
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089 ·Status: COMPLETED ·Phase: NA
-
Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer
NCT04087057 ·Status: COMPLETED
-
Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer
NCT02059876 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
NCT00755313 ·Status: COMPLETED
-
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
NCT00244881 ·Status: COMPLETED ·Phase: PHASE2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT05020860 ·Status: RECRUITING ·Phase: PHASE2
-
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)
NCT00081510 ·Status: COMPLETED ·Phase: PHASE2
-
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
NCT00007904 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast
NCT00788112 ·Status: COMPLETED ·Phase: PHASE1
-
Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer
NCT00005908 ·Status: COMPLETED ·Phase: PHASE2
-
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00005970 ·Status: COMPLETED ·Phase: PHASE3
-
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
NCT04108858 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
NCT05257395 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
NCT07057427 ·Status: RECRUITING ·Phase: PHASE3
-
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023 ·Status: RECRUITING ·Phase: NA
-
"Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
NCT03072992 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Breast Cancer
NCT00003088 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
NCT00668616 ·Status: COMPLETED ·Phase: PHASE3
-
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
NCT05287308 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
NCT00770809 ·Status: COMPLETED ·Phase: PHASE3
-
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
NCT00436709 ·Status: UNKNOWN ·Phase: NA